The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
Status:
Completed
Trial end date:
1994-01-01
Target enrollment:
Participant gender:
Summary
To test the safety and tolerance of three different doses of recombinant human interleukin 2
(aldesleukin; IL-2), when it is given for five consecutive days to patients with AIDS or AIDS
related complex (ARC), who have also received zidovudine (AZT) for at least 6 weeks just
before beginning the IL-2 treatment.
AZT is an antiviral drug, which has been shown to be beneficial in some patients with AIDS.
IL-2 is a substance found naturally in the body that boosts the body's immune response to
invading organisms and tumor cells. These two drugs, when administered together, may have a
mutually helpful effect in treating AIDS patients, but before this effect can be studied, it
is important to understand the proper dose and any side effects that may occur when these
drugs are used together. The study will show how much AZT and IL-2 patients can safely take
at the same time and how the two drugs will interact with each other.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)